Effect of miR‑19b on the protective effect of Exendin‑4 on islet cells in non‑obese diabetic mice

He,Jinshui; Kang,Yueya; Lian,Chaowei; Wu,Jinzhi; Zhou,Huowang; Ye,Xiaoling

doi:10.3892/etm.2019.7598

Effect of miR‑19b on the protective effect of Exendin‑4 on islet cells in non‑obese diabetic mice

Authors:
- Jinshui He
- Yueya Kang
- Chaowei Lian
- Jinzhi Wu
- Huowang Zhou
- Xiaoling Ye
View Affiliations

Affiliations: Department of Pediatrics, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China, Department of Endocrinology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, P.R. China
Published online on: May 22, 2019 https://doi.org/10.3892/etm.2019.7598
Pages: 503-508
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study analyzed the effect of miR‑19b on the protective effect of Exendin‑4 on islet cells in non‑obese diabetic (NOD) mice. Twenty‑four NOD/LT mice were randomized, according to the random number table, into a control group (4 µg/kg•day), a low‑dose group (2 µg/kg•day Exendin‑4), a medium‑dose group (4 µg/kg•day Exendin‑4) and a high‑dose group (8 µg/kg•day Exendin‑4) (n=6), with miR‑19b expression interfered (an interference group) except for the control group. RT‑qPCR was used to detect interference results and different doses of Exendin‑4 were given for 8 weeks of intervention after the interference. CD4+ and CD8+ cell levels were detected by flow cytometry, IL‑2 and IL‑10 levels in the peripheral blood by enzyme‑linked immunosorbent assay, and the apoptosis rate of islet cells in the pancreatic tissue by TUNEL. After 4 and 8 weeks of Exendin‑4 intervention, mice in the high‑dose group had lower blood glucose level than the medium‑dose group (P<0.05). The medium‑dose group had lower CD4+ cell level than the high‑dose group (P<0.05), while the medium‑dose group had higher CD8+ cell level than the high‑dose group (P<0.05). After 8 weeks of intervention, compared with the medium‑dose group, the high‑dose group had lower IL‑2 level (P<0.05), but higher IL‑10 level (P<0.05). After 8 weeks of intervention, the medium‑dose group had a higher apoptosis rate than the high‑dose group (P<0.05). In conclusion, the decrease in miR‑19b expression can improve the therapeutic effect of Exendin‑4 on NOD, control blood glucose effectively and improve inflammatory response and immune function, as well as reduce islet cell injury. The increase in the dose of Exendin‑4 can further improve its therapeutic effect on NOD.

View Figures

View References

1	American Diabetes Association: Standards of medical care in diabetes - 2014. Diabetes Care. 37 (Suppl 1):S14–S80. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pai LW, Hung CT, Li SF, Chen LL, Chung Y and Liu HL: Musculoskeletal pain in people with and without type 2 diabetes in Taiwan: A population-based, retrospective cohort study. BMC Musculoskelet Disord. 16:3642015. View Article : Google Scholar : PubMed/NCBI
3	American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 32 (Suppl 1):S62–S67. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wang Z, York NW, Nichols CG and Remedi MS: Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 19:872–882. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS and Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 28:1083–1091. 2005. View Article : Google Scholar : PubMed/NCBI
6	Tate M, Robinson E, Green BD, McDermott BJ and Grieve DJ: Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol. 111:12016. View Article : Google Scholar : PubMed/NCBI
7	Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, Xifra G, Martínez C, Ricart W, Rieusset J, et al: Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care. 37:1375–1383. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lima TI, Araujo HN, Menezes ES, Sponton CH, Araújo MB, Bomfim LH, Queiroz AL, Passos MA, E Sousa TA, Hirabara SM, et al: Role of microRNAs on the regulation of mitochondrial biogenesis and insulin signaling in skeletal muscle. J Cell Physiol. 232:958–966. 2017. View Article : Google Scholar : PubMed/NCBI
9	Jia Y, Zheng Z, Guan M, Zhang Q, Li Y, Wang L and Xue Y: Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells. Exp Mol Med. 50:562018. View Article : Google Scholar : PubMed/NCBI
10	Guo C, Sun YQ, Li Q and Zhang JC: MiR-7, miR-9 and miR-375 contribute to effect of Exendin-4 on pancreatic β-cells in high-fat-diet-fed mice. Clin Invest Med. 41:E16–E24. 2018. View Article : Google Scholar : PubMed/NCBI
11	Yao Y, Li Q, Wang W, Zhang J, Gao P and Xu Y: Glucagon-like peptide-1 modulates cholesterol homeostasis by suppressing the miR-19b-induced downregulation of ABCA1. Cell Physiol Biochem. 50:679–693. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhou J, Chu J, Wang YH, Wang H, Zhuang YP and Zhang SL: Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in Pichia pastoris. Biotechnol Lett. 30:651–656. 2008. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	NCD Risk Factor Collaboration (NCD-RisC), . Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 387:1513–1530. 2016. View Article : Google Scholar : PubMed/NCBI
15	Nolan CJ, Ruderman NB, Kahn SE, Pedersen O and Prentki M: Insulin resistance as a physiological defense against metabolic stress: Implications for the management of subsets of type 2 diabetes. Diabetes. 64:673–686. 2015. View Article : Google Scholar : PubMed/NCBI
16	Jung HS, Chung KW, Won Kim J, Kim J, Komatsu M, Tanaka K, Nguyen YH, Kang TM, Yoon KH, Kim JW, et al: Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab. 8:318–324. 2008. View Article : Google Scholar : PubMed/NCBI
17	Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM and Tamborlane WV; T1D Exchange Clinic Network, : Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. Diabetes Care. 38:971–978. 2015. View Article : Google Scholar : PubMed/NCBI
18	Ceriello A, La Sala L, De Nigris V, Pujadas G, Rondinelli M and Genovese S: GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress. Ther Clin Risk Manag. 11:901–903. 2015. View Article : Google Scholar : PubMed/NCBI
19	Li C, Hou S, Liu S, Huan Y, Sun S, Liu Q and Shen Z: The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice. BMC Pharmacol Toxicol. 18:482017. View Article : Google Scholar : PubMed/NCBI
20	Candeias E, Sebastião I, Cardoso S, Carvalho C, Santos MS, Oliveira CR, Moreira PI and Duarte AI: Brain GLP-1/IGF-1 signaling and autophagy mediate exendin-4 protection against apoptosis in type 2 diabetic rats. Mol Neurobiol. 55:4030–4050. 2018.PubMed/NCBI
21	He JS, Lian CW, Fang YL, Wu JZ, Ye XL and Zhu SB: Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4. Eur Rev Med Pharmacol Sci. 20:4322–4327. 2016.PubMed/NCBI
22	Jo S, Chen J, Xu G, Grayson TB, Thielen LA and Shalev A: miR-204 controls glucagon-like peptide 1 receptor expression and agonist function. Diabetes. 67:256–264. 2018. View Article : Google Scholar : PubMed/NCBI
23	Li PC, Liu LF, Jou MJ and Wang HK: The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 17:372016. View Article : Google Scholar : PubMed/NCBI
24	Seo E, Lim JS, Jun JB, Choi W, Hong IS and Jun HS: Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing. J Transl Med. 15:352017. View Article : Google Scholar : PubMed/NCBI
25	Lehtonen J, Schäffer L, Rasch MG, Hecksher-Sørensen J and Ahnfelt-Rønne J: Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models. Islets. 7:e11374152015. View Article : Google Scholar : PubMed/NCBI
26	Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, Luan J, Ardanaz E, Arriola L, Balkau B, et al: Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A Meta-analysis. JAMA. 316:1383–1391. 2016. View Article : Google Scholar : PubMed/NCBI